Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

UCL vs TNXP vs AXSM vs GSAT vs IRDM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
UCL
uCloudlink Group Inc.

Telecommunications Services

Communication ServicesNASDAQ • HK
Market Cap$43M
5Y Perf.-93.0%
TNXP
Tonix Pharmaceuticals Holding Corp.

Biotechnology

HealthcareNASDAQ • US
Market Cap$32M
5Y Perf.-100.0%
AXSM
Axsome Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$11.19B
5Y Perf.+164.2%
GSAT
Globalstar, Inc.

Telecommunications Services

Communication ServicesNASDAQ • US
Market Cap$10.56B
5Y Perf.+1575.3%
IRDM
Iridium Communications Inc.

Telecommunications Services

Communication ServicesNASDAQ • US
Market Cap$4.38B
5Y Perf.+63.0%

UCL vs TNXP vs AXSM vs GSAT vs IRDM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
UCL logoUCL
TNXP logoTNXP
AXSM logoAXSM
GSAT logoGSAT
IRDM logoIRDM
IndustryTelecommunications ServicesBiotechnologyBiotechnologyTelecommunications ServicesTelecommunications Services
Market Cap$43M$32M$11.19B$10.56B$4.38B
Revenue (TTM)$85M$10M$708M$283M$876M
Net Income (TTM)$8M$-99M$-188M$-14M$106M
Gross Margin49.8%34.3%92.6%40.9%62.5%
Operating Margin-1.5%-9.7%-24.8%8.6%25.8%
Forward P/E105.5x37.3x
Total Debt$10M$5M$241M$546M$1.76B
Cash & Equiv.$30M$99M$323M$447M$97M

UCL vs TNXP vs AXSM vs GSAT vs IRDMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

UCL
TNXP
AXSM
GSAT
IRDM
StockJun 20May 26Return
uCloudlink Group In… (UCL)1007.0-93.0%
Tonix Pharmaceutica… (TNXP)1000.0-100.0%
Axsome Therapeutics… (AXSM)100264.2+164.2%
Globalstar, Inc. (GSAT)1001675.3+1575.3%
Iridium Communicati… (IRDM)100163.0+63.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: UCL vs TNXP vs AXSM vs GSAT vs IRDM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IRDM leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. uCloudlink Group Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. AXSM and GSAT also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
UCL
uCloudlink Group Inc.
The Defensive Pick

UCL is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 0.59, Low D/E 45.8%, current ratio 1.32x
  • Beta 0.59 vs TNXP's 3.24
  • 11.9% ROA vs TNXP's -39.3%, ROIC 363.4% vs -150.3%
Best for: sleep-well-at-night
TNXP
Tonix Pharmaceuticals Holding Corp.
The Growth Angle

Among these 5 stocks, TNXP doesn't own a clear edge in any measured category.

Best for: healthcare exposure
AXSM
Axsome Therapeutics, Inc.
The Growth Play

AXSM ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 65.5%, EPS growth 38.6%, 3Y rev CAGR 133.7%
  • 18.6% 10Y total return vs GSAT's 204.0%
  • 65.5% revenue growth vs IRDM's 4.9%
Best for: growth exposure and long-term compounding
GSAT
Globalstar, Inc.
The Momentum Pick

GSAT is the clearest fit if your priority is momentum.

  • +306.6% vs TNXP's -25.6%
Best for: momentum
IRDM
Iridium Communications Inc.
The Income Pick

IRDM carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 3 yrs, beta 1.08, yield 1.4%
  • Beta 1.08, yield 1.4%, current ratio 2.48x
  • Better valuation composite
  • 12.1% margin vs TNXP's -9.6%
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthAXSM logoAXSM65.5% revenue growth vs IRDM's 4.9%
ValueIRDM logoIRDMBetter valuation composite
Quality / MarginsIRDM logoIRDM12.1% margin vs TNXP's -9.6%
Stability / SafetyUCL logoUCLBeta 0.59 vs TNXP's 3.24
DividendsIRDM logoIRDM1.4% yield, 3-year raise streak, vs GSAT's 0.1%, (3 stocks pay no dividend)
Momentum (1Y)GSAT logoGSAT+306.6% vs TNXP's -25.6%
Efficiency (ROA)UCL logoUCL11.9% ROA vs TNXP's -39.3%, ROIC 363.4% vs -150.3%

UCL vs TNXP vs AXSM vs GSAT vs IRDM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

UCLuCloudlink Group Inc.
FY 2024
Others Member
100.0%$1M
TNXPTonix Pharmaceuticals Holding Corp.

Segment breakdown not available.

AXSMAxsome Therapeutics, Inc.
FY 2025
Product
100.0%$634M
GSATGlobalstar, Inc.
FY 2025
Service
72.0%$257M
Services, SPOT
10.4%$37M
Commercial loT
7.6%$27M
Product
4.4%$16M
Services, Duplex
4.3%$15M
Services, Other
1.3%$5M
IRDMIridium Communications Inc.
FY 2025
Service
72.7%$634M
Engineering and Support Services
18.0%$157M
Subscription and Circulation
9.3%$81M

UCL vs TNXP vs AXSM vs GSAT vs IRDM — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLUCLLAGGINGAXSM

Income & Cash Flow (Last 12 Months)

IRDM leads this category, winning 3 of 6 comparable metrics.

IRDM is the larger business by revenue, generating $876M annually — 85.0x TNXP's $10M. IRDM is the more profitable business, keeping 12.1% of every revenue dollar as net income compared to TNXP's -9.6%. On growth, AXSM holds the edge at +57.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricUCL logoUCLuCloudlink Group …TNXP logoTNXPTonix Pharmaceuti…AXSM logoAXSMAxsome Therapeuti…GSAT logoGSATGlobalstar, Inc.IRDM logoIRDMIridium Communica…
RevenueTrailing 12 months$85M$10M$708M$283M$876M
EBITDAEarnings before interest/tax$236,000-$98M-$167M$108M$439M
Net IncomeAfter-tax profit$8M-$99M-$188M-$14M$106M
Free Cash FlowCash after capex-$5M-$78M-$71M$45M$305M
Gross MarginGross profit ÷ Revenue+49.8%+34.3%+92.6%+40.9%+62.5%
Operating MarginEBIT ÷ Revenue-1.5%-9.7%-24.8%+8.6%+25.8%
Net MarginNet income ÷ Revenue+9.2%-9.6%-26.6%-5.0%+12.1%
FCF MarginFCF ÷ Revenue-6.4%-7.6%-10.0%+15.8%+34.8%
Rev. Growth (YoY)Latest quarter vs prior year-16.0%+16.6%+57.4%+16.7%+1.9%
EPS Growth (YoY)Latest quarter vs prior year+21.2%-14.6%-3.3%0.0%-25.9%
IRDM leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

UCL leads this category, winning 3 of 6 comparable metrics.

At 1.0x trailing earnings, UCL trades at a 98% valuation discount to IRDM's 39.1x P/E. On an enterprise value basis, UCL's 3.4x EV/EBITDA is more attractive than GSAT's 104.4x.

MetricUCL logoUCLuCloudlink Group …TNXP logoTNXPTonix Pharmaceuti…AXSM logoAXSMAxsome Therapeuti…GSAT logoGSATGlobalstar, Inc.IRDM logoIRDMIridium Communica…
Market CapShares × price$43M$32M$11.2B$10.6B$4.4B
Enterprise ValueMkt cap + debt − cash$23M-$62M$11.1B$10.7B$6.0B
Trailing P/EPrice ÷ TTM EPS0.96x-0.08x-59.07x-547.27x39.11x
Forward P/EPrice ÷ next-FY EPS est.105.50x37.27x
PEG RatioP/E ÷ EPS growth rate0.02x
EV / EBITDAEnterprise value multiple3.44x104.40x13.55x
Price / SalesMarket cap ÷ Revenue0.47x3.16x17.52x38.67x5.03x
Price / BookPrice ÷ Book value/share2.00x0.23x122.48x29.25x9.66x
Price / FCFMarket cap ÷ FCF8.34x137.46x14.62x
UCL leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

UCL leads this category, winning 5 of 9 comparable metrics.

UCL delivers a 32.4% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-3 for AXSM. TNXP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRDM's 3.81x. On the Piotroski fundamental quality scale (0–9), IRDM scores 8/9 vs GSAT's 4/9, reflecting strong financial health.

MetricUCL logoUCLuCloudlink Group …TNXP logoTNXPTonix Pharmaceuti…AXSM logoAXSMAxsome Therapeuti…GSAT logoGSATGlobalstar, Inc.IRDM logoIRDMIridium Communica…
ROE (TTM)Return on equity+32.4%-42.9%-2.6%-3.9%+22.8%
ROA (TTM)Return on assets+11.9%-39.3%-27.8%-0.6%+4.1%
ROICReturn on invested capital+3.6%-150.3%-19.1%+2.3%+8.0%
ROCEReturn on capital employed+21.8%-97.6%-52.1%+0.8%+9.6%
Piotroski ScoreFundamental quality 0–954448
Debt / EquityFinancial leverage0.46x0.04x2.73x1.54x3.81x
Net DebtTotal debt minus cash-$20M-$93M-$82M$99M$1.7B
Cash & Equiv.Liquid assets$30M$99M$323M$447M$97M
Total DebtShort + long-term debt$10M$5M$241M$546M$1.8B
Interest CoverageEBIT ÷ Interest expense22.37x-34.13x2.67x
UCL leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GSAT leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in GSAT five years ago would be worth $50,208 today (with dividends reinvested), compared to $0 for TNXP. Over the past 12 months, GSAT leads with a +306.6% total return vs TNXP's -25.6%. The 3-year compound annual growth rate (CAGR) favors GSAT at 80.5% vs TNXP's -88.9% — a key indicator of consistent wealth creation.

MetricUCL logoUCLuCloudlink Group …TNXP logoTNXPTonix Pharmaceuti…AXSM logoAXSMAxsome Therapeuti…GSAT logoGSATGlobalstar, Inc.IRDM logoIRDMIridium Communica…
YTD ReturnYear-to-date-30.7%-14.9%+21.7%+28.3%+134.3%
1-Year ReturnPast 12 months-4.2%-25.6%+99.7%+306.6%+61.7%
3-Year ReturnCumulative with dividends-72.7%-99.9%+179.7%+488.5%-31.9%
5-Year ReturnCumulative with dividends-91.1%-100.0%+299.7%+402.1%+19.0%
10-Year ReturnCumulative with dividends-93.3%-100.0%+1861.9%+204.0%+427.6%
CAGR (3Y)Annualised 3-year return-35.1%-88.9%+40.9%+80.5%-12.0%
GSAT leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — UCL and GSAT each lead in 1 of 2 comparable metrics.

UCL is the less volatile stock with a 0.59 beta — it tends to amplify market swings less than TNXP's 3.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GSAT currently trades 99.1% from its 52-week high vs TNXP's 20.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricUCL logoUCLuCloudlink Group …TNXP logoTNXPTonix Pharmaceuti…AXSM logoAXSMAxsome Therapeuti…GSAT logoGSATGlobalstar, Inc.IRDM logoIRDMIridium Communica…
Beta (5Y)Sensitivity to S&P 5000.59x3.24x0.67x2.04x1.08x
52-Week HighHighest price in past year$4.19$69.97$233.75$82.85$44.36
52-Week LowLowest price in past year$1.10$11.60$96.09$17.24$15.65
% of 52W HighCurrent price vs 52-week peak+27.4%+20.1%+93.0%+99.1%+93.5%
RSI (14)Momentum oscillator 0–10028.350.875.464.261.7
Avg Volume (50D)Average daily shares traded7K409K658K1.5M2.3M
Evenly matched — UCL and GSAT each lead in 1 of 2 comparable metrics.

Analyst Outlook

IRDM leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: TNXP as "Buy", AXSM as "Buy", GSAT as "Hold", IRDM as "Buy". Consensus price targets imply 17.7% upside for AXSM (target: $256) vs -19.6% for GSAT (target: $66). For income investors, IRDM offers the higher dividend yield at 1.41% vs GSAT's 0.10%.

MetricUCL logoUCLuCloudlink Group …TNXP logoTNXPTonix Pharmaceuti…AXSM logoAXSMAxsome Therapeuti…GSAT logoGSATGlobalstar, Inc.IRDM logoIRDMIridium Communica…
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$255.81$66.00$35.50
# AnalystsCovering analysts725513
Dividend YieldAnnual dividend ÷ price+0.1%+1.4%
Dividend StreakConsecutive years of raises003
Dividend / ShareAnnual DPS$0.08$0.58
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+4.3%
IRDM leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

IRDM leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). UCL leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.

Best OveralluCloudlink Group Inc. (UCL)Leads 2 of 6 categories
Loading custom metrics...

UCL vs TNXP vs AXSM vs GSAT vs IRDM: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is UCL or TNXP or AXSM or GSAT or IRDM a better buy right now?

For growth investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger pick with 65. 5% revenue growth year-over-year, versus 4. 9% for Iridium Communications Inc. (IRDM). uCloudlink Group Inc. (UCL) offers the better valuation at 1. 0x trailing P/E (105. 5x forward), making it the more compelling value choice. Analysts rate Tonix Pharmaceuticals Holding Corp. (TNXP) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — UCL or TNXP or AXSM or GSAT or IRDM?

On trailing P/E, uCloudlink Group Inc.

(UCL) is the cheapest at 1. 0x versus Iridium Communications Inc. at 39. 1x. On forward P/E, Iridium Communications Inc. is actually cheaper at 37. 3x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — UCL or TNXP or AXSM or GSAT or IRDM?

Over the past 5 years, Globalstar, Inc.

(GSAT) delivered a total return of +402. 1%, compared to -100. 0% for Tonix Pharmaceuticals Holding Corp. (TNXP). Over 10 years, the gap is even starker: AXSM returned +1862% versus TNXP's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — UCL or TNXP or AXSM or GSAT or IRDM?

By beta (market sensitivity over 5 years), uCloudlink Group Inc.

(UCL) is the lower-risk stock at 0. 59β versus Tonix Pharmaceuticals Holding Corp. 's 3. 24β — meaning TNXP is approximately 445% more volatile than UCL relative to the S&P 500. On balance sheet safety, Tonix Pharmaceuticals Holding Corp. (TNXP) carries a lower debt/equity ratio of 4% versus 4% for Iridium Communications Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — UCL or TNXP or AXSM or GSAT or IRDM?

By revenue growth (latest reported year), Axsome Therapeutics, Inc.

(AXSM) is pulling ahead at 65. 5% versus 4. 9% for Iridium Communications Inc. (IRDM). On earnings-per-share growth, the picture is similar: uCloudlink Group Inc. grew EPS 1479% year-over-year, compared to 12. 8% for Iridium Communications Inc.. Over a 3-year CAGR, AXSM leads at 133. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — UCL or TNXP or AXSM or GSAT or IRDM?

Iridium Communications Inc.

(IRDM) is the more profitable company, earning 13. 1% net margin versus -1288. 3% for Tonix Pharmaceuticals Holding Corp. — meaning it keeps 13. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRDM leads at 27. 1% versus -1354. 3% for TNXP. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is UCL or TNXP or AXSM or GSAT or IRDM more undervalued right now?

On forward earnings alone, Iridium Communications Inc.

(IRDM) trades at 37. 3x forward P/E versus 105. 5x for uCloudlink Group Inc. — 68. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AXSM: 17. 7% to $255. 81.

08

Which pays a better dividend — UCL or TNXP or AXSM or GSAT or IRDM?

In this comparison, IRDM (1.

4% yield), GSAT (0. 1% yield) pay a dividend. UCL, TNXP, AXSM do not pay a meaningful dividend and should not be held primarily for income.

09

Is UCL or TNXP or AXSM or GSAT or IRDM better for a retirement portfolio?

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 67), +1862% 10Y return). Tonix Pharmaceuticals Holding Corp. (TNXP) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AXSM: +1862%, TNXP: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between UCL and TNXP and AXSM and GSAT and IRDM?

These companies operate in different sectors (UCL (Communication Services) and TNXP (Healthcare) and AXSM (Healthcare) and GSAT (Communication Services) and IRDM (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: UCL is a small-cap deep-value stock; TNXP is a small-cap high-growth stock; AXSM is a mid-cap high-growth stock; GSAT is a mid-cap quality compounder stock; IRDM is a small-cap quality compounder stock. IRDM pays a dividend while UCL, TNXP, AXSM, GSAT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

UCL

Quality Business

  • Sector: Communication Services
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

TNXP

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Gross Margin > 20%
Run This Screen
Stocks Like

AXSM

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 28%
  • Gross Margin > 55%
Run This Screen
Stocks Like

GSAT

High-Growth Disruptor

  • Sector: Communication Services
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Gross Margin > 24%
Run This Screen
Stocks Like

IRDM

Stable Dividend Mega-Cap

  • Sector: Communication Services
  • Market Cap > $100B
  • Net Margin > 7%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform UCL and TNXP and AXSM and GSAT and IRDM on the metrics below

Revenue Growth>
%
(UCL: -16.0% · TNXP: 16.6%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.